ondansetron has been researched along with Disease Exacerbation in 3 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral ondansetron (8 mg) was given 1 h prior to temozolomide administration." | 2.71 | Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. ( Abdulkarim, B; Armand, JP; Cioloca, C; Djafari, L; Djazouli, K; Faivre, S; Guillamo, JS; Osorio, M; Parker, F; Raymond, E; Vera, K, 2004) |
| " Further detailed pharmacokinetic studies of irinotecan in patients receiving concomitant therapy with enzyme-inducing anticonvulsants are required so that rational dosing recommendations can be provided for this patient population." | 1.31 | Influence of phenytoin on the disposition of irinotecan: a case report. ( Berg, S; Bernstein, M; Blaney, SM; Cherrick, I; Kuttesch, N; Murry, DJ; Salama, V, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Simonetto, M | 1 |
| Ferigo, L | 1 |
| Zanet, L | 1 |
| Capus, L | 1 |
| Antonutti, L | 1 |
| Zorzon, M | 1 |
| Pizzolato, G | 1 |
| Vera, K | 1 |
| Djafari, L | 1 |
| Faivre, S | 1 |
| Guillamo, JS | 1 |
| Djazouli, K | 1 |
| Osorio, M | 1 |
| Parker, F | 1 |
| Cioloca, C | 1 |
| Abdulkarim, B | 1 |
| Armand, JP | 1 |
| Raymond, E | 1 |
| Murry, DJ | 1 |
| Cherrick, I | 1 |
| Salama, V | 1 |
| Berg, S | 1 |
| Bernstein, M | 1 |
| Kuttesch, N | 1 |
| Blaney, SM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
1 trial available for ondansetron and Disease Exacerbation
| Article | Year |
|---|---|
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazin | 2004 |
2 other studies available for ondansetron and Disease Exacerbation
| Article | Year |
|---|---|
Acute Akinesia, an unusual complication in Parkinson's Disease: a case report.
Topics: Acute Disease; Aged; Antiparkinson Agents; Apomorphine; Basal Ganglia Diseases; Creatine Kinase; Dis | 2008 |
Influence of phenytoin on the disposition of irinotecan: a case report.
Topics: Adolescent; Anticonvulsants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2002 |